{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:45:33Z","timestamp":1765885533759},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"DOI":"10.1093\/rheumatology\/kei024","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T00:24:47Z","timestamp":1121819087000},"page":"1394-1398","source":"Crossref","is-referenced-by-count":55,"title":["The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database"],"prefix":"10.1093","volume":"44","author":[{"given":"C. J.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. K.","family":"Arden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Saperia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Reading","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. P.","family":"Van Staa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,7,19]]},"reference":[{"key":"key\n\t\t\t\t20171012052534_BIB1","doi-asserted-by":"crossref","unstructured":"Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum2001;44:2746\u20139.","DOI":"10.1002\/1529-0131(200112)44:12<2746::AID-ART461>3.0.CO;2-Z"},{"key":"key\n\t\t\t\t20171012052534_BIB2","doi-asserted-by":"crossref","unstructured":"Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet2002;359:1173\u20137.","DOI":"10.1016\/S0140-6736(02)08213-2"},{"key":"key\n\t\t\t\t20171012052534_BIB3","doi-asserted-by":"crossref","unstructured":"Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum2002;46:328\u201346.","DOI":"10.1002\/art.10148"},{"key":"key\n\t\t\t\t20171012052534_BIB4","doi-asserted-by":"crossref","unstructured":"Alarcon GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum1989;32:671\u20136.","DOI":"10.1002\/anr.1780320603"},{"key":"key\n\t\t\t\t20171012052534_BIB5","doi-asserted-by":"crossref","unstructured":"Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis1995;54:708\u201312.","DOI":"10.1136\/ard.54.9.708"},{"key":"key\n\t\t\t\t20171012052534_BIB6","doi-asserted-by":"crossref","unstructured":"Bologna C, Viu P, Picot MC, Jorgensen C, Sany J. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol1997;36:535\u201340.","DOI":"10.1093\/rheumatology\/36.5.535"},{"key":"key\n\t\t\t\t20171012052534_BIB7","doi-asserted-by":"crossref","unstructured":"Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum1992;35:138\u201345.","DOI":"10.1002\/art.1780350203"},{"key":"key\n\t\t\t\t20171012052534_BIB8","unstructured":"Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol1992;19:1885\u201394."},{"key":"key\n\t\t\t\t20171012052534_BIB9","unstructured":"Rau R, Schleusser B, Herborn G, Karger T. Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol1997;24:1881\u20139."},{"key":"key\n\t\t\t\t20171012052534_BIB10","doi-asserted-by":"crossref","unstructured":"Weinblatt ME, Weissman BN, Holdsworth DE et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum1992;35:129\u201337.","DOI":"10.1002\/art.1780350202"},{"key":"key\n\t\t\t\t20171012052534_BIB11","unstructured":"Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol1990;17:994\u20131002."},{"key":"key\n\t\t\t\t20171012052534_BIB12","unstructured":"Johannes CB, Schneider G, Aygun AC, L'Italien GJ, Viveash D, Wallis WJ. Time to first disease modifying anti-rheumatic drug therapy (DMARD) among rheumatic disease patients in a population based study (abstract). Arthritis Rheum2003;48(Suppl):S337."},{"key":"key\n\t\t\t\t20171012052534_BIB13","unstructured":"The general practice research database: information for researchers. London: Office for National Statistics, 1996."},{"key":"key\n\t\t\t\t20171012052534_BIB14","doi-asserted-by":"crossref","unstructured":"Hall G. Pharmacoepidemiology using a UK database of primary care records. Pharmacoepidemiol Drug Saf1992;1:33\u20137.","DOI":"10.1002\/pds.2630010108"},{"key":"key\n\t\t\t\t20171012052534_BIB15","unstructured":"Hollowell J. General practice research database (GPRD): scope and quality of data. London: Office of Population Censuses and Statistics, 1994."},{"key":"key\n\t\t\t\t20171012052534_BIB16","doi-asserted-by":"crossref","unstructured":"Lis Y, Mann RD. The VAMP research multi-purpose database in the UK. J Clin Epidemiol1995;48:431\u201343.","DOI":"10.1016\/0895-4356(94)00137-F"},{"key":"key\n\t\t\t\t20171012052534_BIB17","unstructured":"Mann RD, Hall G, Chukwujindu J. Research implications of computerised primary care. Post Marketing Surveillance1992;5:259\u201369."},{"key":"key\n\t\t\t\t20171012052534_BIB18","doi-asserted-by":"crossref","unstructured":"van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology2000;39:1383\u20139.","DOI":"10.1093\/rheumatology\/39.12.1383"},{"key":"key\n\t\t\t\t20171012052534_BIB19","doi-asserted-by":"crossref","unstructured":"Walley T, Mantgani A. The UK General Practice Research Database. Lancet1997;350:1097\u20139.","DOI":"10.1016\/S0140-6736(97)04248-7"},{"key":"key\n\t\t\t\t20171012052534_BIB20","doi-asserted-by":"crossref","unstructured":"van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HGM. The use of of a large pharmacoepidemiological database to exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf2000;9:359\u201366.","DOI":"10.1002\/1099-1557(200009\/10)9:5<359::AID-PDS507>3.0.CO;2-E"},{"key":"key\n\t\t\t\t20171012052534_BIB21","doi-asserted-by":"crossref","unstructured":"Lewis JD, Brensinger C, Bilker WB, Strom BL. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf2002;11:211\u201318.","DOI":"10.1002\/pds.698"},{"key":"key\n\t\t\t\t20171012052534_BIB22","unstructured":"Creemers MCW, van de Putte LBA. Rheumatoid arthritis\u2013the clinical picture. In: Isenberg DA, Maddison PJ, Woo P, Glass D, Breedveld FC, eds. Oxford Textbook of Rheumatology, 3rd edn. Oxford: Oxford University Press, 2005."},{"key":"key\n\t\t\t\t20171012052534_BIB23","doi-asserted-by":"crossref","unstructured":"Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology2002;41:793\u2013800.","DOI":"10.1093\/rheumatology\/41.7.793"},{"key":"key\n\t\t\t\t20171012052534_BIB24","doi-asserted-by":"crossref","unstructured":"Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol1994;33:735\u20139.","DOI":"10.1093\/rheumatology\/33.8.735"},{"key":"key\n\t\t\t\t20171012052534_BIB25","doi-asserted-by":"crossref","unstructured":"Chan KW, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum1994;37:814\u201320.","DOI":"10.1002\/art.1780370606"},{"key":"key\n\t\t\t\t20171012052534_BIB26","unstructured":"Harrison BJ, Symmons DP, Brennan P et al. Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. J Rheumatol1996;23:1326\u201331."},{"key":"key\n\t\t\t\t20171012052534_BIB27","doi-asserted-by":"crossref","unstructured":"Newman J, Silman AJ. A comparison of disease status in rheumatoid arthritis patients attending and not attending a specialist clinic. Br J Rheumatol1996;35:1169\u201371.","DOI":"10.1093\/rheumatology\/35.11.1169"},{"key":"key\n\t\t\t\t20171012052534_BIB28","unstructured":"Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol1997;24:2283\u201390."},{"key":"key\n\t\t\t\t20171012052534_BIB29","doi-asserted-by":"crossref","unstructured":"Stross JK. Relationships between knowledge and experience in the use of disease-modifying antirheumatic agents. A study of primary care practitioners. J Am Med Assoc1989;262:2721\u20133.","DOI":"10.1001\/jama.1989.03430190105040"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/44\/11\/1394\/9446095\/kei024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T09:25:56Z","timestamp":1507800356000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/rheumatology\/article\/44\/11\/1394\/1784602\/The-changing-use-of-diseasemodifying-antirheumatic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,19]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2005,7,19]]},"published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kei024","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,11]]},"published":{"date-parts":[[2005,7,19]]}}}